Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus

New England Journal of Medicine

Volumn 333, Issue 9, 1995, Pages 541-549

  Defronzo, Ralph A ^a   Goodman, Anita M ^b  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b Lipha Pharmaceuticals ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYANOCOBALAMIN; FOLIC ACID; GLIBENCLAMIDE; GLYCOSYLATED HEMOGLOBIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LACTIC ACID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; PLACEBO; SULFONYLUREA DERIVATIVE; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DIET THERAPY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; GASTROINTESTINAL SYMPTOM; GLUCOSE BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; ORAL DRUG ADMINISTRATION; ORAL GLUCOSE TOLERANCE TEST; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TABLET; UNITED STATES;

BLOOD GLUCOSE; BODY WEIGHT; CHOLESTEROL; DIABETES MELLITUS; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FASTING; FEMALE; FOLIC ACID; GLUCOSE TOLERANCE TEST; GLYBURIDE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; INSULIN; LACTATES; LACTIC ACID; MALE; METFORMIN; MIDDLE AGED; OBESITY; TREATMENT FAILURE; VITAMIN B 12;

EID: 0029099086     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJM199508313330902     Document Type: Article

References (32)

1. Harris MI, Hadden WC, Knowler WC, Bennett PH Prevalence of diabetes and impaired glucose tolerance and plasma glucose levels in U.S. population aged 20-74 yr. Diabetes 1987; 36: 523-534
2. Groop LC Sulfonylureas in NIDDM. Diabetes Care 1992; 15: 737-754
3. Hermann LS, Melander A. Biguanides: basic aspects and clinical uses: In: Alberti KGM, DeFronzo RA, Keen H, Zimmet P, eds. International textbook of diabetes mellitus. Vol. 1. London: John Wiley, 1992:773-95.
4. Bailey CJ Biguanides and NIDDM. Diabetes Care 1992; 15: 755-772
5. Schafer G Biguanides: a review of history, pharmacodynamics and therapy. Diabetes Metab 1983; 9: 148-163
6. Lucis OJ Status of metformin in Canada. Can Med Assoc J 1983; 128: 24-26
7. DeFronzo RA, Barzilai N, Simonson DC Mechanism of metformin action in obese and lean noninsulin-dependent diabetic subjects. J Clin Endocrinol Metab 1991; 73: 1294-1301
8. Nosadini R, Avogaro A, Trevisian R, Effect of metformin on insulin-stimulated glucose turnover and insulin binding to receptors in type II diabetes. Diabetes Care 1987; 10: 62-67
9. Johnson AB, Webster JM, Sum C-F, The impact of metformin therapy on hepatic glucose production and skeletal muscle glycogen synthase activity in overweight type II diabetic patients. Metabolism 1993; 42: 1217-1222
10. Perriello G, Misericordia P, Volpi E, Acute antihyperglycemic mechanisms of metformin in NIDDM: evidence for suppression of lipid oxidation and hepatic glucose production. Diabetes 1994; 43: 920-928
11. Widen EIM, Eriksson JG, Groop LC Metformin normalizes nonoxidative glucose metabolism in insulin-resistant normoglycemic first-degree relatives of patients with NIDDM. Diabetes 1992; 41: 354-358
12. Hother-Nielsen O, Schmitz O, Andersen PH, Beck-Nielsen H, Pedersen O Metformin improves peripheral but not hepatic insulin action in obese patients with type II diabetes. Acta Endocrinol Suppl (Copenh) 1989; 120: 257-265
13. Klip A, Leiter LA Cellular mechanism of action of metformin. Diabetes Care 1990; 13: 696-704
14. Reaven GM, Johnston P, Hollenbeck CB, Combined metformin-sulfonylurea treatment of patients with noninsulin-dependent diabetes in fair to poor glycemic control. J Clin Endocrinol Metab 1992; 74: 1020-1026
15. Campbell IW Metformin and the sulphonylureas: the comparative risk. Horm Metab Res Suppl 1985; 15: 105-111
16. Nagi DK, Yudkin JS Effects of metformin on insulin resistance, risk factors for cardiovascular disease, and plasminogen activator inhibitor in NIDDM subjects: a study of two ethnic groups. Diabetes Care 1993; 16: 621-629
17. Nutritional recommendations and principles for people with diabetes mellitus. Diabetes Care 1994; 17: 519-522
18. Charles BG, Jacobsen NW, Ravenscroft PJ Rapid liquid-chromatographic determination of metformin in plasma and urine. Clin Chem 1981; 27: 434-436
19. SAS language and procedure guides for personal computers, release 6.03 ed. Cary, N.C.: SAS Institute, 1988.
20. Neter J, Wasserman W, Kutner MH. Applied linear statistical models: regression, analysis of variance, and experimental designs. 2nd ed. Homewood, Ill.: Richard D. Irwin, 1985:517-635, 663-797, 844-89.
21. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 977-986
22. Klein R, Klein BE, Moss SE, Davis MD, DeMets DL The Wisconsin epidemiologic study of diabetic retinopathy. III. Prevalence and risk of diabetic retinopathy when age at diagnosis is 30 or more years. Arch Ophthalmol 1984; 102: 527-532
23. Nathan DM, Singer DE, Godine JE, Harrington CH, Perlmuter LC Retinopathy in older type II diabetes: association with glucose control. Diabetes 1986; 35: 797-801
24. Shank ML, Del Prato S, DeFronzo RA Bedtime insulin/daytime glipizide: effective therapy for sulfonylurea failures in NIDDM. Diabetes 1995; 44: 165-172
25. Rossetti L, Giaccari A, DeFronzo RA Glucose toxicity. Diabetes Care 1990; 13: 610-630
26. DeFronzo RA, Bonadonna RC, Ferrannini E Pathogenesis of NIDDM: a balanced overview. Diabetes Care 1992; 15: 318-368
27. Wollen N, Bailey CJ Inhibition of hepatic gluconeogenesis by metformin: synergism with insulin. Biochem Pharmacol 1988; 37: 4353-4358
28. Cusi K, Consoli A Effect of metformin on glucose and lactate metabolism in NIDDM. Diabetes 1994; 43: Suppl 1: 258A-258A abstract.
29. Landin K, Tengborn L, Smith U Treating insulin resistance in hypertension with metformin reduces both blood pressure and metabolic risk factors. J Intern Med 1991; 229: 181-187
30. Cohen RD The relative risks of different biguanides in the causation of lactic acidosis. Res Clin Forums 1979; 1: 125-134
31. Berger W Incidence of severe side effects during therapy with sulfonylureas and biguanides. Horm Metab Res Suppl 1985; 15: 111-115
32. Wiholm BE, Myrhed M Metformin-associated lactic acidosis in Sweden 1977-1991. Eur J Clin Pharmacol 1993; 44: 589-591